EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC : Insights From Pathology and Clinical Response to Tarlatamab

Shotaro Kaneko, Naoki Furuya, Yoshihisa Sugiura, Hajime Tsuruoka, Kazuhiro Nishiyama, Honoka Morita, Tomoki Okura, Hisashi Saji, Junki Koike, Nobuyuki Ohike, Masamichi Mineshita

Thoracic Cancer · 2026-10 · 17 (20)

DOI: 10.1111/1759-7714.70400 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung neuroendocrine neoplasm with poor prognosis. Recently, DLL3‐targeted bispecific T‐cell engagers (BiTEs) have shown promising efficacy in small cell lung cancer, and clinical trials are ongoing in LCNEC. This study evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy. Methods We retrospectively reviewed consecutive patients who were diagnosed with LCNEC. Immunohistochemical analyses for DLL3 and CD8 were performed. DLL3 positivity was defined as staining in ≥ 1% of tumor cells. CD8+ TIL infiltration was graded as low, moderate, or high. Results Among 77 screened LCNEC cases, 44 were eligible for analysis. The median age was 75 years. DLL3 expression was observed in 70.5% of cases and was associated with worse survival. Low CD8+ TIL infiltration was observed in 59.1% of cases. Patients with high CD8+ TIL infiltration demonstrated significantly longer survival than those with low infiltration ( p = 0.03). Among representative clinical cases, a patient with DLL3 (+)/CD8 TILs (−) LCNEC achieved marked tumor shrinkage, whereas a patient with DLL3 (−)/CD8 TILs (−) LCNEC showed no response. Conclusions DLL3 is frequently expressed in LCNEC and correlates with a poorer prognosis. A majority of LCNEC cases are immunologically characterized as cold tumors lacking CD8+ TILs, which contributes to unfavorable clinical outcomes. Tarlatamab induced a robust antitumor response even in a DLL3 (+) cold tumor. DLL3‐BiTE represents a promising therapeutic strategy for DLL3 (+) LCNEC.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →